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Abstract
Background—The human papillomavirus (HPV) vaccine was recommended in 2007 by the 
Advisory Committee on Immunization Practices (ACIP) to preadolescent and adolescent girls. 
Vaccination initiation was recommended at age 11–12 years with the option to start at age 9. 
Catchup vaccination was recommended to females aged 13–26 previously not vaccinated. 
However, vaccination coverage remains low. Studies show that the HPV vaccine can prevent 
cervical, vulvar, vaginal, anal and some oropharyngeal cancers and that provider recommendation 
of vaccines can improve low vaccination rates.
Methods—Using data from 2012 DocStyles, an annual, web-based survey of U.S. healthcare 
professionals including physicians and nurse practitioners (n = 1753), we examined providers’ 
knowledge about the effectiveness of the HPV vaccine in preventing cancer and their vaccine 
recommendation to all age-eligible females (9–26 years). Descriptive statistics and Chi-square 
tests were used to assess differences across specialties.
Results—Knowledge about HPV vaccine effectiveness in preventing cervical cancer was highly 
prevalent (96.9%), but less so for anal, vaginal, vulvar and oropharyngeal cancers. Only 14.5% of 
providers recommended the vaccine to all age-eligible females and 20.2% recommended it to 
females aged 11–26 years. Knowledge assessment of cancers associated with HPV and 
vaccination recommendations varied significantly among providers (p < 0.01). Providers more 
frequently recommended the vaccine to girls older than 11–12 years.
Conclusions—Improving providers’ knowledge about HPV-associated cancers and the age for 
vaccination initiation, communicating messages focusing on the vaccine safety and benefits in 
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cancer prevention and on the importance of its delivery prior to sexual onset, may improve HPV 
vaccine coverage.
Keywords
HPV vaccine recommendations; Cervical, anal, vaginal, vulvar and cancers; Vaccine initiation; 
HPV vaccine knowledge
Introduction
In 2007, the human papillomavirus (HPV) vaccine was first recommended by the Advisory 
Committee on Immunization Practices (ACIP) for routine vaccination of preadolescent and 
adolescent girls (Markowitz et al., 2014); (Markowitz et al., 2007). ACIP recommended a 3-
dose series of the vaccine targeted to girls aged 11–12 years. However, the recommendation 
also pointed out that the vaccine could be administered to girls starting at age 9 years. Catch-
up vaccination was recommended to females aged 13–26 years who had not been 
vaccinated. In 2011, the vaccine was also recommended for males aged 13 to 21 years who 
had not been previously vaccinated or who had not completed the 3-dose series. The ACIP 
also recommended that males aged 22 to 26 years may be vaccinated (Centers for Disease 
Control and Prevention, 2011).
HPV vaccine coverage remains low in the U.S. In 2013, complete (three doses) of vaccine 
uptake was estimated at 37.6% among females aged 13–17 years (Dunne et al., 2014). Even 
with a low HPV vaccination coverage, there has been a 56% reduction in vaccine-specific 
HPV infections among females aged 14–19 years in the US from 2003–2006, the period 
before vaccine initiation, to 2007–2010, the period after initiation. Provider recommendation 
of the vaccine has repeatedly been associated with much greater odds of vaccination uptake 
(Reiter et al., 2009); (Daley et al., 2010); (Brewer et al., 2011); (Rosenthal et al., 2011); (Lau 
et al., 2012); (Gargano et al., 2013); (Ylitalo et al., 2013). Providers with knowledge and 
understanding of the burden of disease may be more likely to recommend the vaccine, 
consistent with guidelines (Daley et al., 2010).
HPV can cause cancers of the cervix, vulva, vagina, penis, or anus. It can also cause cancer 
of the back of the throat, including the base of the tongue and tonsils (Saraiya et al., 2015). 
Information on HPV associated cancers, which physicians believed the HPV vaccine can 
prevent, had been published previously (Saraiya et al., 2012). However, to our knowledge, 
no previous studies have assessed the full spectrum of the age range for which HPV 
vaccination was recommended. Our study examined more current data on providers’ beliefs 
about the effectiveness of the HPV vaccine in preventing cancer and their recommended age 
groups for vaccinating females aged 9–26 years, by provider specialty, to identify measures 
which may increase vaccine uptake.
Materials and methods
Data source
DocStyles is an annual web-based survey of U.S. healthcare professionals that investigates 
provider attitudes and practices related to various health issues. The survey was administered 
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online by Porter Novelli Public Services (Porter Novelli, Washington, DC) with guidance 
provided by federal public health agencies and other clients. Quota sampling is used to 
warrant the adequate representation of targeted provider specialties.
Participants were recruited from the Epocrates Honors Panel, a market research panel 
comprised of over 275,000 medical practitioners and 750,000 allied health professionals. 
Physicians’ verification was completed at the time of panel registration and was achieved by 
checking each physician’s name, date of birth, medical school, and graduation date against 
the American Medical Association’s (AMA) Masterfile, an inventory of licensed U.S. 
physicians. A random sample of physicians was then selected to match the AMA file 
proportion for age, gender and region. The sample of nurse practitioners was drawn from a 
list of 78,668 nurse practitioners in the Epocrates Allied Health Panel but no verification of 
identities or demographic thresholds was performed. Providers were eligible to participate in 
the 2012 DocStyles survey if they actively saw patients, worked in an individual, group, or 
hospital practice, and actively practiced medicine for a minimum of 3 years in the U.S.
The Centers for Disease Control and Prevention (CDC) licensed items on the 2012 
DocStyles survey to monitor knowledge of gynecologic cancer screening and prevention 
practices among health-care providers. Therefore, this survey assessed provider beliefs on 
HPV vaccination only in females. This project was exempt from CDC IRB because personal 
identifiers were not included in the data file. A variety of provider groups were recruited, but 
responses to all items analyzed in our study were limited to family medicine/general 
practitioners (fm/GPs), internists, nurse practitioners (NPs), pediatricians, and obstetrician/
gynecologists (OB/GYNs). A randomly selected sample of providers was invited to 
participate in the survey. Sampling quotas were set to reach 1000 fm/GPs and internists and 
250 of each of the other specialties. In July 2012, an email invitation to participate in the 
DocStyles survey was sent to 2175 fm/GPs and internists, 456 NPs, 518 pediatricians and 
489 OB/GYNs. Completed responses were obtained from 1753 providers, with an overall 
response rate of 52.2%. Specialty response rates were 49.9% for fm/GPs and internists (only 
aggregate number was provided), 65.4% for NPs, 53.5% for pediatricians and 55.2% for 
OB/GYNs. Providers who did not meet the screening criteria (n = 71) and those who did not 
complete the survey (n = 75) were excluded. The remaining providers were removed when 
the quota was filled.
Analysis
Our outcomes of interest included: 1) HPV vaccination recommendations, and 2) provider 
knowledge of HPV vaccine effectiveness in cancer prevention. The first outcome was 
measured with the question “To which age groups of female patients do you typically 
recommend the HPV vaccine? Select all that apply”. Answer choices included 8 years and 
younger, 9–10 years, 11–12 years, 13–17 years, 18–26 years, 27–30 years, 31 years and 
older, and I do not recommend the HPV vaccine. The second outcome was measured with 
the question “The HPV vaccine is effective in preventing which of the following? Select all 
that apply.” Choices included cancers associated with HPV (cervical cancer, vulvar cancer, 
vaginal cancer, anal cancer, and oropharyngeal cancer), and cancers not associated with 
HPV (ovarian cancer, uterine cancer and skin cancer), and none of these. Other variables of 
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interest included demographic characteristics (gender, race/ethnicity, and number of years in 
practice), practice characteristics (practice setting, number of providers in the practice, and 
geographic region), and patient characteristics (number of patients seen weekly, seeing 
patients < 18 years, and percent of female patients ages 18–26). All five provider specialties 
were asked the questions about HPV vaccine knowledge and beliefs. The responses to these 
questions may reflect not only the age groups providers see in their practice but what they 
might recommend to parents with children at eligible HPV vaccination age.
Descriptive statistics were conducted to assess the distributions of demographic, practice and 
patient characteristics and were stratified by provider specialty. We also calculated 
percentages of physicians in each specialty selecting the specified age groups, the cancers 
associated with HPV, and the percentages of mutually exclusive combinations of these 
selections. Chi-square tests were used to examine differences across specialties. All analyses 
were conducted using SAS 9.3 (SAS Institute, Cary, NC). A p-value < 0.05 was considered 
significant.
Results
Most provider and practice characteristics varied significantly by provider type (Table 1). 
The majority of respondents were male (60.1%), non-Hispanic white (74.2%), in a group 
outpatient work setting (73.8%), working with 2 or more practitioners (84.7%), and except 
for NPs, more than 50% saw 100 or more patients a week.
Across all specialties, 54.9% of providers recommended the HPV vaccine to females aged 
11–12 years (Fig. 1). Specialty responses ranged from 30.4% among internists to 74.0% 
among pediatricians (p < 0.001). Providers more frequently recommended HPV vaccination 
for females aged 13–17 years (66.9%) with percentages ranging from 46.1% among 
internists to 78.4% among pediatricians (p < 0.001). The percentage of providers who 
recommended the vaccine to females aged 18–26 years was 63.3% and ranged from 54.7% 
and 55.6% among internists and pediatricians respectively to 78.4% among OB/GYNs (p < 
0.001). Overall recommendations to females aged 9–10 years was 22.6%, of which OB/
GYNs had the highest percentage (38.0%, p < 0.001). Nearly 2% of providers recommended 
the vaccine to females younger than 9 years and 15.5% recommended it to females older 
than 26 years.
Table 2 describes the patterns of mutually exclusive age groups to which providers 
recommended the HPV vaccine. Among providers recommending the vaccine within the 
age-eligible range, 14.5% recommended it to females 9–26 years old, 20% recommended it 
to females 11–26 years, and 42% recommended the vaccine to females in various subsets of 
age groups within the eligible age range. Vaccination recommendations differed significantly 
(p < 0.001) among the 5 types of providers. OB/GYNs had the highest percentage of their 
specialty recommending the vaccine to females aged 9–26 (29.2%), pediatricians most 
frequently recommended the vaccine to females aged 11 –26 (32.4%) and internist most 
often (18.7%) recommended the vaccine to females aged 18–26 years.
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Twelve percent of providers recommended combinations of age groups outside the age-
eligible range, with the largest percentages being among fm/GPs, OB/GYNs and internists 
(15.5%, 13.6% and 13.4% respectively). More than 11.0% did not recommend the vaccine to 
any age group. Internist comprised the largest percentage (23.9%) of providers who did not 
recommend the vaccine.
Almost all providers were aware that the HPV vaccine was effective in preventing cervical 
cancer (96.9%), with responses ranging from 94.8% among NPs to 99.2% among both 
pediatricians and OB/GYNs (p = 0.001; Fig. 2). However, their awareness of the vaccine’s 
effectiveness of anal, oropharyngeal, vulvar, and vaginal cancers was lower and varied 
between specialties (p < 0.001 for each cancer type respectively). OB/GYNs had the highest 
percentage of knowledge about the vaccine’s potential effectiveness for anal, vulvar, and 
vaginal cancers (63.2%, 56.4% and 45.2% respectively) and internists had the lowest 
(40.5%, 20.5%, and 17.0% respectively). The percentage of physicians reporting that HPV is 
effective in preventing oropharyngeal cancer was highest among pediatricians (38%) with a 
slightly lower response by OB/GYNs (34%), and the lowest among internists (20.3%). Less 
than 4% of providers selected the choices of uterine, ovarian, and skin cancers, and none of 
these cancers.
Patterns of beliefs about the effectiveness of the HPV vaccine in preventing various 
combinations of cancers varied by specialty (Table 3). Among the mutually exclusive 
combination choices which were analyzed, only 6.4% of all providers selected anal, cervical, 
vaginal and vulvar cancers without selecting any other cancer. OB/GYNs were more likely 
to select this combination than any other specialty (12.4%, P < 0.001). The largest group of 
providers (39.9%) selected cervical cancer as the only cancer prevented by the HPV vaccine 
with internists having the largest proportion of their specialty selecting it (46.8%). The 
selection of cervical cancer in various combinations with anal, vaginal and vulvar cancers, 
comprised 21.4% and ranged from 20.9% among internists to 27.6% among OB/GYNs (p < 
0.001). Ten percent of providers selected anal, cervical, vaginal, vulvar and oropharyngeal 
cancers. OB/GYNs had the highest percentage (22.4%) and internists the lowest (5.0%, p < 
0.001). Combinations of cervical cancer with anal, vaginal, vulvar and oropharyngeal 
cancers were selected by 13.5% of providers with pediatricians having the highest 
percentage (23.2%). Finally, nearly 9% of providers selected answers with one or more 
cancer (skin, uterine and ovarian cancers), which are not considered to be caused by HPV, or 
with none of these cancers. Among those, NPs had the highest percentage (15.9%) of 
selection and OB/GYNs the lowest (2.8%).
Discussion
Our study identified the range of age groups of females for whom providers recommended 
HPV vaccination, and provider knowledge of which cancers can be prevented with the HPV 
vaccine—characteristics that might shed light on the low vaccination rate among females 
aged 11–26 years.
Consistent with previous studies, our findings show that providers more often recommended 
the vaccine to females aged 13–17 years and 18–26 years than to females aged 11–12 years, 
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the target age for vaccination initiation (Reiter et al., 2009); (Daley et al., 2010); (Rahman et 
al., 2015). Only one out of 5 providers recommended vaccination to females in the age range 
of 11–26 years. An additional 14.5% recommended it to those aged 9–26 years, the full age 
spectrum of age-eligible groups. A barrier contributing to the lower vaccination proportion 
of preadolescents might be the 11% of providers who did not recommend the HPV vaccine 
at all. Further examination of these providers’ beliefs about the vaccine is warranted. An 
additional area of improvement is related to providers’ knowledge of the age-group eligible 
for HPV vaccination. Many providers selected ages younger or older than the ages 
recommended by the ACIP. Education and messages targeting providers about the 
recommended ages of initiation and catchup vaccination would be beneficial.
Our findings were also consistent with findings of a previous DocStyles study conducted in 
2009, which included only the 4 physician specialty groups (Saraiya et al., 2012). In both 
studies, a very high percentage of providers recognized that the HPV vaccine is effective in 
preventing cervical cancer. However, in 2012, after the anal efficacy trial was published 
(Palefsky et al., 2011); (Giuliano et al., 2011) recognition of the vaccine in preventing anal 
cancer doubled among all physicians. A similar increase occurred for the selection of 
oropharyngeal cancer, albeit with smaller percentages. This finding is interesting, given that 
there is no clinical trial showing prevention of oropharyngeal cancer. The potential of the 
vaccine role in preventing oropharyngeal cancer is based on epidemiological research, which 
has shown that certain types of oropharyngeal cancer are attributable to HPV infection 
(especially HPV 16) and on indirect evidence suggesting prevention of oral HPV infection 
(Herrero et al., 2013). A much more modest increase (between < 1% to 4%) among the 4 
physician groups occurred for the selection of vulvar cancer, and the change for vaginal 
cancer selection was not consistent.
Our study suggests that much improvement could be made in providers’ knowledge of HPV 
vaccine, and its potential role in preventing anal, vaginal, vulvar and oropharyngeal cancers 
in addition to cervical cancer, the only familiar site to all providers. Furthermore, knowledge 
about the association of HPV with both anal and oropharyngeal cancer can potentially 
promote the vaccine to males, who currently have a much lower uptake than females (Elam-
Evans et al., 2014); (Committee on Infectious Diseases, 2012); (McRee et al., 2014). A 
recent study addressing gaps in physicians’ knowledge about the HPV vaccine and its 
applications found that a brief educational intervention using structured presentations 
increased providers’ HPV vaccine knowledge among a variety of healthcare providers 
(Berenson et al., 2015).
Adolescent vaccination coverage of HPV vaccine is generally lower than that of other 
recommended adolescent vaccines (Elam-Evans et al., 2014); (Schwartz and Easterling, 
2015) namely tetanus and meningococcal, and much lower than vaccination coverage of 
children and infants (Elam-Evans et al., 2014). Unlike younger age groups, this group does 
not have preventive visits as often as when vaccinations are most commonly given, thus 
reducing opportunities for immunizations (Rand et al., 2007); (Committee on Infectious 
Diseases, 2012); (The president cancer panel, 2014). Bundling the HPV vaccine with other 
vaccines administered to preadolescent and young adolescents can potentially increase 
vaccine initiation substantially, as was previously recommended by the 2012–2013 
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President’s Cancer Panel and currently by the CDC (The president cancer panel, 2014); 
(Dunne et al., 2014). A study based on the National Immunization-Teen Survey found that 
provider recommendation to co-administer the HPV and meningococcal vaccines increased 
the odds of HPV vaccination by 3-folds among girls who received meningococcal 
vaccination and reduced missed opportunities to initiate the HPV vaccine series (Perkins et 
al., 2015).
The lower percentage of vaccine recommendations to females aged 11–12, the age of 
vaccine initiation, may result in a delay in vaccine initiation and may explain the low rate of 
vaccination completion at ages 13–17 years (Williams et al., 2015). Reluctance to 
recommend the HPV vaccine to preadolescent girls may be associated with the perception 
that young girls are at low risk of HPV infection, which is a sexually transmitted infection, 
and the hesitation to discuss sexual health-related issues with them and their parents 
(Committee on Infectious Diseases, 2012); (Daley et al., 2010); (Kahn et al., 2005). In a 
survey of U.S. physicians 18 months after the HPV vaccine licensure, Daley et al. observed 
that physicians’ reluctance to recommend the vaccine stemmed also from the time it takes to 
discuss vaccination, and reports that parents of 11–12 years old female patients are more 
likely to refuse vaccination than those of older patients. However, physicians who did not 
intend to defer vaccination to an older age and those with a high load of publicly insured 
patients were more likely to strongly recommend the vaccine to this age group. Additionally, 
if the discussion about the HPV vaccine emphasized cancer prevention at the time children 
are coming for scheduled immunization, and occurred before sexual onset, the first uptake of 
the vaccine might increase substantially (Kahn et al., 2005); (Rand et al., 2007); (Shefer et 
al., 2008).
OB/GYNs had the highest percentage of knowledge about the benefits of the HPV vaccine 
in preventing cancer. Knowledge about the burden of disease is a factor in improving 
vaccination uptake. Following the example of advocacy by the American College of 
Obstetricians and Gynecologists (ACOG) to their constituency (Committee on Adolescent 
Health Care of the American College of Obstetricians and Gynecologists and Immunization 
Expert Work Group of the American College of Obstetricians and Gynecologists, 2014), 
priming parents of children ages younger than 11 about the vaccine benefits to preadolescent 
girls and its safety (Schwarz et al., 2012) may decrease parents’ anxiety and help increase 
vaccination initiation substantially. This approach may also work for other provider 
specialties who may not care directly for adolescents but may have the opportunity to 
educate parents about the benefits of the HPV vaccine for younger patients. Targeting at a 
younger age is a more useful strategy than giving the vaccine at ages 21 to 26, when most 
females are already exposed to HPV (Joura et al., 2015).
There are a number of limitations to our findings. First, the method of recruitment may 
introduce some bias. Responses to e-mail invitations were collected on a first-come, first-
served basis, turning away respondents after the quota for their specialty had been filled. 
However, the ability to answer the survey over three weeks helped achieve above-average 
response rates ranging from 50% to 65% for all specialties. Additionally, an analysis 
performed by Porter Novelli comparing demographic variables of participants in 2012 
DocStyles with physicians in the AMA Masterfile found that, although the percentages of 
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pediatricians and OB/GYN who responded were higher than expected, the percentages of 
fm/GPs and internists, participants’ ages, and regions distributions were fairly comparable. 
Focusing on female vaccination is another limitation. Assessment of male recommendations 
was excluded because the survey items were part of a project focused on gynecological 
cancer. An important limitation of the study is the inclusion of providers who did not care 
for children aged < 18 or 9–10 year olds. Some of these providers’ recommendations might 
have focused on their patient population and less on the age range for vaccination. However, 
asking all providers about the ages for whom they recommend the HPV vaccine, including 
age groups which are not part of their patient population, may be part of preventive 
messages the clinicians are giving to parents or grandparents. The inclusion of only 2 items 
related to HPV vaccination in the survey is another limitation. However, the questions about 
physician’s knowledge may point out the gap in knowledge about the burden of disease, 
which had been shown to have an impact on vaccine recommendations. Lastly, there were no 
questions regarding provider attitudes about the HPV vaccine.
Conclusions
Our study revealed that a relatively small percentage of providers recommended the full age 
range of vaccination. Moreover, providers more often recommended the vaccine to females 
at ages older than the target age for the HPV vaccine initiation (11–12 years). Additionally, 
providers were most familiar with the potential benefits of the HPV vaccine in preventing 
cervical cancer but were found to have gaps in knowledge about the other HPV associated 
cancers. These age groups preferences and the gap in providers’ knowledge about the ACIP 
guidelines may delay vaccination initiation and suggest that a large number of eligible 
females in the U.S. may not receive appropriate recommendations for the HPV vaccine. 
Bundling the vaccine with other early adolescent immunizations, improving provider 
knowledge about HPV-associated cancers and the eligible age for vaccination, 
communicating messages that focus on the vaccine safety and benefits in cancer prevention 
and on the importance of its delivery prior to sexual onset, (American Academy of 
Pediatrics, 2015) may lead to a substantial improvement in HPV vaccine coverage.
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Fig. 1. 
Age groups of females to which providers typically recommended the HPV vaccine, by 
provider specialty, DocStyles survey 2012 (N = 1753).
aPercentages do not include providers who did not recommend the vaccine to females. 
*Significant differences (p < 0.001) by physician specialty for each age group included in 
the age-eligible range. Percentage differences were assessed with chi-square tests.
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Fig. 2. 
Cancers which providers believed are prevented by the HPV vaccine, by provider specialty, 
DocStyles survey 2012 (N = 1753)a.
aThree cancer types not associated with HPV were also available to select including ovarian, 
skin, uterine cancers and none of the above. However responses to these cancers were 
selected by < 9% of physicians of any specialty. *Significant differences (p < 0.01) by 
provider specialty for each cancer site. Percentage differences were assessed with Chi-
square tests.
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